Validating GSK3 as an in vivo target of lithium action.

Lithium is widely used to treat bipolar disorder, but its mechanism of action in this disorder is unknown. Lithium directly inhibits GSK3 (glycogen synthase kinase 3), a critical regulator of multiple signal transduction pathways. Inhibition of GSK3 provides a compelling explanation for many of the known effects of lithium, including effects on early development and insulin signalling/glycogen synthesis. However, lithium also inhibits inositol monophosphatase, several structurally related phosphomonoesterases, phosphoglucomutase and the scaffolding function of beta-arrestin-2. It is not known which of these targets is responsible for the behavioural or therapeutic effects of lithium in vivo. The present review discusses basic criteria that can be applied to model systems to validate a proposed direct target of lithium. In this context, we describe a set of simple behaviours in mice that are robustly affected by chronic lithium treatment and are similarly affected by structurally diverse GSK3 inhibitors and by removing one copy of the Gsk3b gene. These observations, from several independent laboratories, support a central role for GSK3 in mediating behavioural responses to lithium.

[1]  S. Ju,et al.  Glycogen synthase kinase‐3 is required for optimal de novo synthesis of inositol , 2007, Molecular microbiology.

[2]  R. Belmaker,et al.  Behavioural phenotyping of sodium‐myo‐inositol cotransporter heterozygous knockout mice with reduced brain inositol , 2007, Genes, brain, and behavior.

[3]  H. Manji,et al.  Generation and behavioral characterization of β-catenin forebrain-specific conditional knock-out mice , 2008, Behavioural Brain Research.

[4]  H. Manji,et al.  β-Catenin Overexpression in the Mouse Brain Phenocopies Lithium-Sensitive Behaviors , 2007, Neuropsychopharmacology.

[5]  T. Steckler,et al.  Transgenic Mice Overexpressing Glycogen Synthase Kinase 3β: A Putative Model of Hyperactivity and Mania , 2006, The Journal of Neuroscience.

[6]  K. Roth,et al.  Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: Protection by mood stabilizers and imipramine , 2005, Biological Psychiatry.

[7]  C. Phiel,et al.  Inhibitory Phosphorylation of Glycogen Synthase Kinase-3 (GSK-3) in Response to Lithium , 2003, Journal of Biological Chemistry.

[8]  J. Woodgett,et al.  Glycogen Synthase Kinase-3β Haploinsufficiency Mimics the Behavioral and Molecular Effects of Lithium , 2004, The Journal of Neuroscience.

[9]  W. Ray,et al.  The binding of lithium and of anionic metabolites to phosphoglucomutase. , 1978, Biochimica et biophysica acta.

[10]  A. Harwood,et al.  A common mechanism of action for three mood-stabilizing drugs , 2002, Nature.

[11]  D. Chuang,et al.  Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[13]  T. Steckler,et al.  Lack of Lithium-Like Behavioral and Molecular Effects in IMPA2 Knockout Mice , 2007, Neuropsychopharmacology.

[14]  W. Sherman,et al.  The Effects of Lithium on myo‐Inositol Levels in Layers of Frontal Cerebral Cortex, in Cerebellum, and in Corpus Callosum of the Rat , 1980, Journal of neurochemistry.

[15]  P. S. Klein,et al.  Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. , 1997, Developmental biology.

[16]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[17]  J. Acharya,et al.  Synaptic Defects and Compensatory Regulation of Inositol Metabolism in Inositol Polyphosphate 1-Phosphatase Mutants , 1998, Neuron.

[18]  A. Harwood,et al.  Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. , 2001, Biochemical and biophysical research communications.

[19]  Michael J. Berridge,et al.  Neural and developmental actions of lithium: A unifying hypothesis , 1989, Cell.

[20]  P. S. Klein,et al.  Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease. , 2006, Current drug targets.

[21]  W. Sherman,et al.  The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. , 1980, The Journal of biological chemistry.

[22]  J. Huhta,et al.  Molecular effects of lithium exposure during mouse and chick gastrulation and subsequent valve dysmorphogenesis. , 2008, Birth defects research. Part A, Clinical and molecular teratology.

[23]  R. Rodriguiz,et al.  A β-arrestin 2 Signaling Complex Mediates Lithium Action on Behavior , 2008, Cell.

[24]  R. Belmaker,et al.  SMIT1 haploinsufficiency causes brain inositol deficiency without affecting lithium-sensitive behavior. , 2006, Molecular genetics and metabolism.

[25]  P. Greengard,et al.  GSK-3-selective inhibitors derived from Tyrian purple indirubins. , 2003, Chemistry & biology.

[26]  Abraham Weizman,et al.  Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on β-catenin in mouse hippocampus , 2004, Biological Psychiatry.

[27]  M. Deardorff,et al.  Kermit, a frizzled interacting protein, regulates frizzled 3 signaling in neural crest development. , 2001, Development.

[28]  J. Greer,et al.  Loss of Murine Na+/myo-Inositol Cotransporter Leads to Brain myo-Inositol Depletion and Central Apnea* , 2003, The Journal of Biological Chemistry.

[29]  D. Melton,et al.  A molecular mechanism for the effect of lithium on development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Ávila,et al.  Lithium inhibits Alzheimer's disease‐like tau protein phosphorylation in neurons , 1997, FEBS letters.

[31]  Jacqueline N. Crawley,et al.  What's Wrong With My Mouse?: Behavioral Phenotyping of Transgenic and Knockout Mice , 2000 .

[32]  R. Belmaker,et al.  Homozygote inositol transporter knockout mice show a lithium-like phenotype. , 2008, Bipolar disorders.

[33]  Kathleen E. Rankin,et al.  Regulation of Glycogen Synthase Kinase 3β and Downstream Wnt Signaling by Axin , 1999, Molecular and Cellular Biology.

[34]  R. Jope,et al.  Lithium and brain signal transduction systems. , 1994, Biochemical pharmacology.

[35]  J. York,et al.  An expanded view of inositol signaling. , 2001, Advances in enzyme regulation.

[36]  J. York,et al.  A role for a lithium-inhibited Golgi nucleotidase in skeletal development and sulfation , 2008, Proceedings of the National Academy of Sciences.

[37]  J. Baraban.  Toward a crystal-clear view of lithium's site of action. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[38]  P. S. Klein,et al.  Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. , 2002, Pharmacology & therapeutics.

[39]  Y. Maeda,et al.  INFLUENCE OF IONIC CONDITIONS ON CELL DIFFERENTIATION AND MORPHOGENESIS OF THE CELLULAR SLIME MOLDS , 1970, Development, growth & differentiation.

[40]  Jacqueline N. Crawley,et al.  What's Wrong With My Mouse? , 2007 .

[41]  Virginia M. Y. Lee,et al.  Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3* , 1997, The Journal of Biological Chemistry.

[42]  Douglas S. Williams,et al.  Switching on a signaling pathway with an organoruthenium complex. , 2005, Angewandte Chemie.

[43]  D. M. Ferkey,et al.  GBP, an Inhibitor of GSK-3, Is Implicated in Xenopus Development and Oncogenesis , 1998, Cell.

[44]  H. Manji,et al.  AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. , 2004, The international journal of neuropsychopharmacology.

[45]  H. Strutt,et al.  Glycogen synthase kinase 3 regulates cell fate in dictyostelium , 1995, Cell.

[46]  M. Lu,et al.  Wnt/beta-catenin signaling promotes expansion of Isl-1-positive cardiac progenitor cells through regulation of FGF signaling. , 2007, The Journal of clinical investigation.

[47]  T. Steckler,et al.  IMPA1 is Essential for Embryonic Development and Lithium-Like Pilocarpine Sensitivity , 2008, Neuropsychopharmacology.

[48]  J. Woodgett,et al.  Essential Roles for GSK-3s and GSK-3-Primed Substrates in Neurotrophin-Induced and Hippocampal Axon Growth , 2006, Neuron.

[49]  T. Sotnikova,et al.  Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[50]  P. Maycox,et al.  The common inositol-reversible effect of mood stabilizers on neurons does not involve GSK3 inhibition, myo-inositol-1-phosphate synthase or the sodium-dependent myo-inositol transporters , 2006, Molecular and Cellular Neuroscience.

[51]  A. Harwood,et al.  The mood stabiliser lithium suppresses PIP3 signalling in Dictyostelium and human cells , 2009, Disease Models & Mechanisms.